Sign in
CompletedNo phase

Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment

Key facts

Who runs it
Capital Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
380 people enrolled
Started
1 Nov 2024
Ended
1 Jun 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Vitamin D3 (800 IU/d) and Folic Acid(0.4mg/d)
  • Vitamin D3 (1600 IU/d) and Folic Acid(0.4mg/d)
  • Starch Placebo
Record updated
30 October 2026

Who can take part

Age
50 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Aged 50 to 70 years old
  • Derived from the established elderly chronic disease and health cohort
  • Meet the diagnostic criteria for Mild Cognitive Impairment (MCI) (e.g., indicated by specific cut-off scores on the MoCA adjusted for education level)
  • Volunteered to participate, able to cooperate with the cognitive assessments, and signed the informed consent form

Who cannot take part

  • Current use or use within the past 3 months of cognition-improving drugs, Vitamin D, or Folic Acid supplements, and unwilling to undergo a 3-month washout period prior to the intervention
  • Diagnosis of Alzheimer's disease, other types of dementia, or severe psychiatric disorders (e.g., severe depression, schizophrenia)
  • History of severe neurological diseases (e.g., stroke, brain tumor, brain trauma) that may affect cognitive function
  • Patients with liver diseases (e.g., hepatitis, liver cirrhosis) or kidney diseases (e.g., nephritis, kidney stones, renal failure)
  • Patients with hypercalcemia (serum calcium concentration > 10.5 mg/dl)
  • Severe visual or hearing impairments that prevent the completion of cognitive tests
  • Patients with severe anemia, severe malnutrition, or abnormal thyroid function

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to investigate the effects of Vitamin D3 combined with Folic Acid on mild cognitive impairment (MCI). Participants aged 50 to 70 years with MCI will be randomly assigned to three groups: a low-dose Vitamin D3 plus Folic Acid group, a high-dose Vitamin D3 plus Folic Acid group, and a placebo group. The intervention will last for 6 months. The main goal is to observe whether this nutritional intervention can improve or delay the decline of cognitive function.

The 3 groups in the trial

  • 800IU/d Vitamin D3 + Folic AcidTreatment being tested

    Participants will receive one folic acid(0.4mg/d) tablet and one low-dose(800IU/d) Vitamin D3 tablet orally once daily at breakfast for 6 months.

    Treatment: Vitamin D3 (800 IU/d) and Folic Acid(0.4mg/d)

  • 1600IU/d Vitamin D3 + Folic AcidTreatment being tested

    Participants will receive one folic acid(0.4mg/d) tablet and one high-dose(1600IU/d) Vitamin D3 tablet orally once daily at breakfast for 6 months.

    Treatment: Vitamin D3 (1600 IU/d) and Folic Acid(0.4mg/d)

  • PlaceboPlacebo, for comparison

    Participants will receive two starch placebo tablets (identical in appearance, color, and smell to the active supplements) orally once daily at breakfast for 6 months.

    Treatment: Starch Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects and Mechanisms of Vitamin D Combined With Folic Acid and Vitamin B12 on Mild Cognitive Impairment Via Regulation of Key Factors in 27-Hydroxycholesterol Metabolism
Record updated
30 October 2026